AtaiBeckley Inc. 4

In the September 11, 2026 Eli Lilly buyout of AtaiBeckley Inc., insider Christian Angermayer disposed of all 55,756,748 directly and indirectly held common shares and all options, converting them into cash and CVRs at the $6.75-per-share merger price.

On September 11, 2026, in connection with the closing of Eli Lilly’s acquisition of AtaiBeckley Inc., all of Christian Angermayer’s direct and indirect holdings of AtaiBeckley common stock and all of his stock options were terminated in exchange for the cash-and-contingent-value-right (CVR) merger consideration, resulting in zero remaining equity ownership. This included (i) 559,232 shares of common stock held directly, (ii) 53,398,214 shares held indirectly through Apeiron Investment Group Ltd., and (iii) 1,799,302 shares held indirectly through Apeiron Presight Capital Fund II, L.P., all converted into the right to receive $6.75 per share in cash plus one CVR per share. In addition, multiple tranches of stock options covering an aggregate of 2,320,528 shares with exercise prices ranging from $1.64 to $5.68 and expirations between August 20, 2030 and June 4, 2036 were canceled and converted into cash payments equal to the in-the-money value based on the $6.75 merger price plus one CVR per underlying share. The Form 4 also corrects a previously misstated beneficial ownership total, but after giving effect to the merger and option cancellations, Angermayer no longer owns any AtaiBeckley equity securities.

Filing Facts

CIK

2081043

Ticker

ATAI

Form

4

Source Type

fda

Accession

0001140361-26-036377

Alert Tier

6